Palbociclib and pembrolizumab for advanced sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs, palbociclib and pembrolizumab, in people with certain types of advanced sarcoma (cancer of the soft tissues) that have continued to grow despite prior treatment. It aims to see if this combination can shrink tumors or slow down the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older.
- You must have one of these sarcoma types: undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, or alveolar soft part sarcoma.
- Your cancer must have grown or spread after at least one previous treatment.
- You must be able to walk and do light activities (ECOG score of 0, 1, or 2).
- You cannot have untreated or active brain metastases, but treated brain metastases that are stable are okay.
- You must have adequate organ function as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving pembrolizumab along with chemotherapy delivered directly into an arm or leg (isolated limb infusion) can shrink sarcoma tumors. It is for people with advanced or metastatic sarcoma in an arm or leg who can safely have this local treatment.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This trial tests whether pembrolizumab, an immunotherapy that helps your immune system attack cancer cells, can shrink or slow growth in several ultra-rare sarcoma types that have come back or spread. It may be an option if your previous treatments have stopped working.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
This trial tests a combination of paclitaxel polymer micelles with other drugs for people with advanced bone or soft tissue sarcoma that has worsened after first-line chemotherapy. The goal is to see if this new formulation can help shrink tumors or slow their growth.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.